BEIJING, April 26,
2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc.
(NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical
company focused on developing and commercializing innovative
therapeutics and pharmaceutical products, today announced that it
filed its annual report on Form 20-F for the fiscal year ended
December 31, 2022, with the U.S.
Securities and Exchange Commission ("SEC") on April 26, 2023. The annual report can be accessed
on the Company's investor relations website at
https://www.casipharmaceuticals.com/investor-relations/ as well as
the SEC's website at https://www.sec.gov/.
The Company will provide a hard copy of its annual report
containing the audited consolidated financial statements, free of
charge, to its shareholders upon request. Requests should be
directed to Investor Relations Department, CASI Pharmaceuticals,
Inc., Rm 1701-1702, China Central
Office Tower 1, No.81 Jianguo Road Chaoyang District, Beijing, 100025, China.
About CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. is a biopharmaceutical company
focused on developing and commercializing innovative therapeutics
and pharmaceutical products in China, the United
States, and throughout the world. The Company is focused on
acquiring, developing, and commercializing products that augment
its hematology oncology therapeutic focus as well as other areas of
unmet medical need. The Company intends to execute its plan to
become a leader by launching medicines in the Greater China market, leveraging the Company's
China-based regulatory and
commercial competencies and its global drug development expertise.
The Company's operations in China
are conducted through its wholly-owned subsidiary, CASI
Pharmaceuticals (China) Co., Ltd.,
located in Beijing, China. The
Company has built a commercial team of more than 100 hematology and
oncology sales and marketing specialists based in China. More information on CASI is available
at www.casipharmaceuticals.com.
For more information, please contact:
Company Contact:
CASI Pharmaceuticals,
Inc.
Rui Zhang
240-864-2643
ir@casipharmaceuticals.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-files-annual-report-on-form-20-f-for-fiscal-year-2022-301808180.html
SOURCE CASI Pharmaceuticals, Inc.